Now to Slide 6 and 7 where I'll discuss the segment results for the quarter. In Early Development, pro forma net revenue was $215 million. This represents a $3.7 million sequential increase on a rebound in discovery support and clinical pharmacology, which more than offset a decline in research products and toxicology. Continuing operations in toxicology, it is when excluding Chandler in both periods, was up sequentially. This is a 7.1% year-on-year reduction, driven by a decline in revenues in toxicology, research products and foreign exchange headwinds as well as the exclusion of revenues from the 3 facilities for which closure activities have commenced in 2012.Read the rest of this transcript for free on seekingalpha.com
Covance Management Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.